Hyperpigmentation Disorders Treatment Market Size was valued at USD 4.9 billion in 2023 and is projected to grow from USD 5.23 Billion in 2024 to USD 8.79 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.60% during the forecast period (2024 - 2032). Rising demand for advanced treatments for pigmentation disorders is projected to fuel the market for pigmentation disorder treatments during the forecast period. These are some of the market drivers that are boosting the market for hyperpigmentation disorders treatment.
Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review
The rising number of people going through pigmentation disorders is one of the significant reasons for the pigmentation disorder treatment market growth. India, China, and other Asian countries have a large inpatient pool agonizing from this disorder, and this consequence generated the need for powerful treatments for pigmentation disorders. For that reason, the R&D initiatives taken by leading market players are participated to stimulate market growth. Additionally, massive government spending on the biotechnology and pharmaceutical sectors in progressing nations, an extension of healthcare infrastructure, and an increase in demand for evolving treatments for pigmentation disorders are expected to fuel the pigmentation disorder treatment market during the forecast period.
Further, Increasing awareness about pigmentation disorders is anticipated to fetch market growth during the study period. Various government organizations have taken measures to make people aware of pigmentation disorder. There is no indefinite cure for a few pigmentations, such as vitiligo conditions and albinism, and the cost of light therapy is enormous. Formulas are incredibly high in rates. Also, depending on the treated skin area, the cost of other treatments, like laser therapy, varies for reimposing pigmentation. Thus, many treatments for pigmentation disorders are projected to bind the acquiring treatments. Therefore, this factor is enhancing the market CAGR for hyperpigmentation disorders treatment during the forecast period.
Figure 1: Hyperpigmentation Disorders Treatment Market around the globe
Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review
However, the rise in the frequency of melasma and the rise in preference for cosmeceutical treatment have led to significant demand for dermatological care. Melasma was remarkably widespread in 2020, conditioning more than 5 million people in the U.S. Asian women of childbearing age face a prevalence of about 30%, which is challenging to treat. As per worldwide hyperpigmentation disorders treatment market trends, treatment options are projected to fetch growth in the forthcoming years. Moreover, significant trends in the pigmentation disorders treatment market are the rising focus on the betterment of safe and effective pigmentation disorders treatment. Market players are focusing on progressing and bringing safer treatments into the market due to the rise in pigmentation disorders frequency and increased demand for better treatments. This is anticipated to continue over the forecast period, driving the market growth.
Nonetheless, the rising awareness amongst people about several dermatological disorders has led to more expenditure on dermatological treatments, which is further related to increased living standards and per capita income globally. This shows the rise in more cost of dermatological treatments, fueling the growth of pigmentation disorders treatment market globally during the forecast period. Thus, it is forecasted that this aspect will drive hyperpigmentation disorders treatment market revenue globally.
The market segments of hyperpigmentation disorders treatment, based on treatment type, includes tropical drugs, chemical peels, and laser therapy. The Tropical drugs segment held the majority share in 2022 in the Hyperpigmentation Disorders Treatment Market data. Due to upgraded clinical results in singles with pigmentation disorders, topical therapy dominates the global market. Azelaic acid, hydroquinone, L-ascorbic acid, and other topical medications are the most commonly used across the globe.
Based on disease indication, the Hyperpigmentation Disorders Treatment Market segmentation includes melasma and solar lentigines. The melasma segment dominated the market growth for hyperpigmentation disorders treatment in 2022 and is projected to be the faster-growing segment during the forecast period, 2023-2032. Melasma is currently leading the illness type sector because of its high incidence rate in white people, which is responsible for 55% to 60% of the world population. Melasma affects 90% of women globally, bringing about hormonal fluctuations, pregnancy, and birth control drugs.
Figure 2: Hyperpigmentation Disorders Treatment Market, by Disease Indication, 2022 & 2032 (USD Billion)
Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review
The Market data of Hyperpigmentation Disorders Treatment, based on end users, includes hospitals and others. The hospitals' segment dominated the market revenue of hyperpigmentation disorders treatment in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. This segment is driven by an increase in dermatological and aesthetic clinics.
However, the others segment is also expected to rise during the forecast period. To address the rising demand for treatments for hyperpigmentation disorders, producers and dealers of cosmeceuticals for hyperpigmentation are enhancing their supply chains.
The study states the market insights for hyperpigmentation disorders treatment into North America, Asia- Pacific, Europe, and the Rest of the world by region. The North American hyperpigmentation disorders treatment market accounted for USD 4.6 billion in 2022, with a share of around 45.80%, and is anticipated to raise the bar of CAGR growth during the forecast period. The rising frequency of hyperpigmentation disorders is the core reason for this region’s growth since it established healthcare infrastructure for the same and the presence of major market players offering post-inflammatory hyperpigmentation patients effective treatment options.
Further, the significant countries studied in the market report for hyperpigmentation disorders treatment are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: HYPERPIGMENTATION DISORDERS TREATMENT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, MRFR Database, Primary Research, and Analyst Review
Europe's hyperpigmentation disorders treatment market accounts for the second-largest market share due to the high frequency of pigmentation disorders amongst the senior population in these regions, and Europe is home to one of the world's oldest populations, those ages 65 and above, which is to duel the market for this region. Moreover, the UK market of hyperpigmentation disorders treatment held the largest market share, and the German market of hyperpigmentation disorders treatment was the fastest-growing market in the area.
Asia Pacific hyperpigmentation disorders treatment Market is anticipated to rise at the fastest CAGR from 2024 - 2032. This is attributed to the rising awareness of hyperpigmentation disorders, rapidly developing healthcare technology, the vast patient population, and high healthcare expenditure. Further, the China market of hyperpigmentation disorders treatment held the largest market share, and the India market of hyperpigmentation disorders treatment was the fastest growing market in the region.
Hyperpigmentation Disorders Treatment major Market Players & Competitive Insights
Major market players are expending a lot of money on research and development to increase their product lines, which will add to the growing market of hyperpigmentation disorders treatment. Competitors are also taking various strategic initiatives to grow their global footprint, with key market developments such as new product launches, mergers and acquisitions, contractual agreements, increased investments, and collaboration with other organizations. Market participants in the hyperpigmentation disorders treatment industry must provide low-cost products to expand and pull through in a highly competitive and increasing market environment.
One of the primary business strategies producers adopt in the global hyperpigmentation disorders treatment industry to satisfy clients and enlarge the market sector is to produce narrowly to reduce operating costs. In recent years, the hyperpigmentation disorders treatment industry has offered medication with some of the most notable benefits. The significant players in market of hyperpigmentation disorders treatment are Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Galderma laboratories (Nestle Skin Health S.A), SkinCeuticals International, and others.
On August 1863, dye salesman Friedrich Bayer and master dyer Johann Friedrich Weskott founded the general partnership "Friedr. Bayer et comp.," and the company enjoyed quick growth. The financial base for expansion was laid in 1881 when Bayer was converted into a joint stock company. The company is mainly engaged in discovering, enriching, producing, and commercializing products for human health and agriculture. It provides medicines for various diseases, women's health, cancer, hematology, ophthalmology, and other indications. It strives to develop new molecules and technologies for treatment and modern agriculture.
SkinCeuticals was founded by Dr. Sheldon Pinnell in 1997 and is based in New York. The company provides a range of skincare solutions like sunscreens, anti-oxidants, facial cleaners, masks, moisturizers, serums, and creams, intended to improve skin health.
Key Companies in the market of Hyperpigmentation Disorders Treatment include
Hyperpigmentation Disorders Treatment Industry Developments
Galderma Laboratories agreed to be in an exclusive license agreement with Sol-Gel Technologies to commercialize the latter's investigational drug products, which employ its proprietary microencapsulation technology. Sol-Gel Technologies is a clinical-stage dermatology company specializing in identifying, progressing, and commercializing branded and generic topical drug products to treat skin diseases.
October 2021: a novel treatment named Vitellus was introduced by the prominent player Uniza Healthcare. This treatment is the unique combination of EUK-134, Greyverse, and Melitane GL 200 that has a tie-up with a Canadian company to manage vitiligo in the Indian market.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 4.9 billion |
| Market Size 2024 | USD 5.23 billion |
| Market Size 2032 | USD 8.79 billion |
| Compound Annual Growth Rate (CAGR) | 6.60% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 – 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Growth Factors, Market Competitive Landscape, and Trends |
| Segments Covered | Treatment Type, Disease Indication and End User |
| Geographies Covered | North America, Asia-Pacific, Europe, and the Rest of the World |
| Countries Covered | The U.S, Canada, France, Germany, the UK, Italy, China, India, Spain, Japan, Australia, South Korea, and Brazil |
| Key Companies Profiled | Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Galderma laboratories (Nestle Skin Health S.A) |
| Key Market Opportunities | · Rising demands for Outpatient and Minimally Invasive |
| Key Market Dynamics | · Increasing Investment in R&D by Major Players · a consistent stream of new product launches |
Hyperpigmentation Disorders Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Hyperpigmentation Disorders Treatment Market size was valued at USD 4.9 Billion in 2023.
The global market for hyperpigmentation disorders treatment is projected to rise at a CAGR of 6.60% during the forecast period 2024-2032.
North America has held the largest share of the global market for hyperpigmentation disorders treatment.
The major players in the market for hyperpigmentation disorders treatment are Allergan, Inc., Bayer AG, EpiPharm AG, Episciences, Galderma laboratories (Nestle Skin Health S.A), SkinCeuticals International, and others.
The tropical drugs category dominated the market for hyperpigmentation disorders treatment in 2023.
The hospitals had the largest share of the global market for hyperpigmentation disorders treatment.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
